Don't miss our weekly PhD newsletter | Sign up now Don't miss our weekly PhD newsletter | Sign up now

We have 359 drug PhD Projects, Programmes & Scholarships

Discipline

Discipline

All disciplines

Location

Location

All locations

Institution

Institution

All Institutions

PhD Type

PhD Type

All PhD Types

Funding

Funding

All Funding


drug PhD Projects, Programmes & Scholarships

We have 359 drug PhD Projects, Programmes & Scholarships

Pharmacokinetics Guided Natural Products Exploration for Drug Discovery, Development, Delivery and Therapy

  Research Group: Institute of Cancer Therapeutics
Natural products have emerged as a key standard in novel and safe delivery of anticancer bioactive compounds. Apart from their ease of administration and delivery, natural/phytochemicals still face several hurdles, due to their physiochemical and pharmacokinetic properties. Read more

Development of antibody-drug conjugates (ADCs) for oncology indications

  Research Group: Institute of Cancer Therapeutics
A major challenge in cancer therapy is to develop therapeutic agents that selectively target tumour cells but are not harmful to normal tissue. Read more

Combining CRISPR-screens and AI to Identify Novel Therapeutic Strategies to Target Cancer-Stroma Interactions

A fully funded PhD Studentship is available to work with Dr Angus Cameron, Reader in Cell Signalling and Tumour Cell Biology, Barts Cancer Institute at Queen Mary University London, Dr Otto Morris, Senior Biological Data Scientist at Exscientia, and Professor Pedro Cutillas, Professor of Cell Signalling and Proteomics, QMUL, Barts Cancer Institute at Queen Mary University London. Read more

PhD Studentship in “Multi-scale mathematical models to predict prostate cancer progression and treatment response.” (2024)

PhD studentship in the Groups of “Mathematics Applied to Biology” and “Numerical Analysis and Scientific Computing” at the University of Sussex (UK), with the collaboration of the “Group of Numerical Methods in Engineering” at the University of A Coruña (Spain). Read more

Novel strategies and innovative technologies to produce amorphous solid dispersion

Poor drug solubility presents a major challenge in drug product development of oral solid dosage (OSD) forms. However, many new development compounds exhibit poor solubility and only a few of them reach market approval. Read more

Cardiovascular and Neuromuscular Functions around the Clock: Harnessing Protective Endogenous Mechanisms towards Smarter Design of Novel Therapies and Interventions

Optimal tissue and organ is essential for long-term health and quality of life. One such important regulator within the body is related to circadian rhythms, which control ~24h cycles in many physiological processes such as sleep/wake cycles, physical activity/rest cycles, drug metabolism and hormones. Read more

Design, synthesis and evaluation of protease-activated anti-cancer prodrugs

  Research Group: Institute of Cancer Therapeutics
Matrix metalloproteinases (MMPs) are a family of endoproteases that are overexpressed in tumours and play crucial roles in many tumourigenic processes, not least tumour invasion and angiogenesis. Read more

Transcriptome biomarkers and mechanisms of chemoresistance

Project Summary. This project aims to identify biomarkers linked to the most potent multimodal anticancer therapy with the least toxicity to counteract hemoresistance in head and neck squamous cell carcinoma (HNSCC). Read more

Towards the development of a novel class of broad-spectrum anti-infective drugs

Through exceptionally strong research collaborations at the interface of chemistry, biology, and medicine, we have applied innovative thinking to the field of (Minor Groove Binders) MGBs to develop a novel platform for drug discovery with the potential to treat an impressive range of diseases, including bacterial, fungal, parasitic, and viral infections. Read more

Lessening Health Inequalities in Type 2 Diabetes Through Innovative Drug Repurposing

Most older type 2 diabetes (T2D) drugs were developed through pre-clinical studies and then trials that model T2D as it is experienced by older white people (1). Read more

Filtering Results